Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 345

1.

Patients with isolated pulmonary embolism in comparison to those with deep venous thrombosis. Differences in characteristics and clinical evolution.

Palareti G, Antonucci E, Dentali F, Mastroiacovo D, Mumoli N, Pengo V, Poli D, Testa S, Pujatti PL, Menditto VG, Imberti D, Fontanella A.

Eur J Intern Med. 2019 Sep 7. pii: S0953-6205(19)30310-3. doi: 10.1016/j.ejim.2019.08.023. [Epub ahead of print]

PMID:
31500936
2.

Triple Antiphospholipid (aPL) Antibodies Positivity Is Associated With Pregnancy Complications in aPL Carriers: A Multicenter Study on 62 Pregnancies.

Lazzaroni MG, Fredi M, Andreoli L, Chighizola CB, Del Ross T, Gerosa M, Kuzenko A, Raimondo MG, Lojacono A, Ramazzotto F, Zatti S, Trespidi L, Meroni PL, Pengo V, Ruffatti A, Tincani A.

Front Immunol. 2019 Aug 14;10:1948. doi: 10.3389/fimmu.2019.01948. eCollection 2019.

3.

Comparison of real world and core laboratory lupus anticoagulant results from the Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) clinical database and repository.

Efthymiou M, Mackie IJ, Lane PJ, Andrade D, Willis R, Erkan D, Sciascia S, Krillis S, Bison E, Borges Galhardo Vendramini M, Romay-Penabad Z, Qi M, Tektonidou M, Ugarte A, Chighizola C, Belmont HM, Aguirre MA, Ji L, Branch DW, de Jesus G, Fortin PR, Andreoli L, Petri M, Cervera R, Rodriguez E, Knight JS, Atsumi T, Vega J, Sevim E, Bertolaccini ML, Pengo V, Cohen H; APS ACTION.

J Thromb Haemost. 2019 Jul 30. doi: 10.1111/jth.14596. [Epub ahead of print]

PMID:
31364274
4.

Antiplatelet treatment in acute coronary syndrome patients: Real-world data from the START-Antiplatelet Italian Registry.

Marcucci R, Patti G, Calabrò P, Gori AM, Grossi G, Cirillo P, Pengo V, Gresele P, Pignatelli P, Antonucci E, di Mario C, Valente S, Palareti G.

PLoS One. 2019 Jul 15;14(7):e0219676. doi: 10.1371/journal.pone.0219676. eCollection 2019.

5.

Balloon Pulmonary Angioplasty in Patients With Chronic Thromboembolic Pulmonary Hypertension - A Systematic Review and Meta-Analysis.

Zoppellaro G, Badawy MR, Squizzato A, Denas G, Tarantini G, Pengo V.

Circ J. 2019 Jul 25;83(8):1660-1667. doi: 10.1253/circj.CJ-19-0161. Epub 2019 Jun 21.

6.

Antiphospholipid Syndrome in Chronic Thromboembolic Pulmonary Hypertension: A Well-Defined Subgroup of Patients.

Jiang X, Du Y, Cheng CY, Denas G, Zhou YP, Wu T, Zhang YX, Han ZY, Pengo V, Jing ZC.

Thromb Haemost. 2019 Sep;119(9):1403-1408. doi: 10.1055/s-0039-1692428. Epub 2019 Jun 21.

PMID:
31226720
7.

Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis.

Chinnaraj M, Planer W, Pengo V, Pozzi N.

Blood Adv. 2019 Jun 11;3(11):1738-1749. doi: 10.1182/bloodadvances.2019030932.

8.

The adjusted global antiphospholipid syndrome score (aGAPSS) and the risk of recurrent thrombosis: Results from the APS ACTION cohort.

Radin M, Sciascia S, Erkan D, Pengo V, Tektonidou MG, Ugarte A, Meroni P, Ji L, Belmont HM, Cohen H, Ramires de Jesús G, Branch DW, Fortin PR, Andreoli L, Petri M, Rodriguez E, Rodriguez-Pinto I, Knight JS, Atsumi T, Willis R, Gonzalez E, Lopez-Pedrera R, Rossi Gandara AP, Borges Gualhardo Vendramini M, Banzato A, Sevim E, Barbhaiya M, Efthymiou M, Mackie I, Bertolaccini ML, Andrade D; APS ACTION.

Semin Arthritis Rheum. 2019 May 2. pii: S0049-0172(19)30090-3. doi: 10.1016/j.semarthrit.2019.04.009. [Epub ahead of print]

PMID:
31153708
9.

EULAR recommendations for the management of antiphospholipid syndrome in adults.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, Ruiz-Irastorza G, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM.

Ann Rheum Dis. 2019 Oct;78(10):1296-1304. doi: 10.1136/annrheumdis-2019-215213. Epub 2019 May 15.

PMID:
31092409
10.

Real-world persistence with direct oral anticoagulants (DOACs) in naïve patients with non-valvular atrial fibrillation.

Ferroni E, Gennaro N, Costa G, Fedeli U, Denas G, Pengo V, Corti MC.

Int J Cardiol. 2019 Aug 1;288:72-75. doi: 10.1016/j.ijcard.2019.04.061. Epub 2019 Apr 19.

PMID:
31043323
11.

Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants.

Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A, Palareti G; Coordinator of START2-Register.

J Thromb Haemost. 2019 Jul;17(7):1064-1072. doi: 10.1111/jth.14457. Epub 2019 May 26.

PMID:
31013383
12.

The European Registry on Obstetric Antiphospholipid Syndrome (EUROAPS): A survey of 1000 consecutive cases.

Alijotas-Reig J, Esteve-Valverde E, Ferrer-Oliveras R, Sáez-Comet L, Lefkou E, Mekinian A, Belizna C, Ruffatti A, Tincani A, Marozio L, Espinosa G, Cervera R, Ríos-Garcés R, De Carolis S, Latino O, LLurba E, Chighizola CB, Gerosa M, Pengo V, Lundelin K, Rovere-Querini P, Canti V, Mayer-Pickel K, Reshetnyak T, Hoxha A, Tabacco S, Stojanovich L, Gogou V, Varoudis A, Arnau A, Ruiz-Hidalgo D, Trapé J, Sos L, Stoppani C, Martí-Cañamares A, Farran-Codina I; EUROAPS Study Group.

Autoimmun Rev. 2019 Apr;18(4):406-414. doi: 10.1016/j.autrev.2018.12.006. Epub 2019 Feb 15.

PMID:
30772493
13.

The comparison of real world and core laboratory antiphospholipid antibody ELISA results from antiphospholipid syndrome alliance for clinical trials & international networking (APS ACTION) clinical database and repository analysis.

Sciascia S, Willis R, Pengo V, Krilis S, Andrade D, Tektonidou MG, Ugarte A, Chighizola C, Branch DW, Levy RA, Nalli C, Fortin PR, Petri M, Rodriguez E, Rodriguez-Pinto I, Atsumi T, Nascimento I, Rosa R, Banzato A, Erkan D, Cohen H, Efthymiou M, Mackie I, Bertolaccini ML; APS ACTION.

Thromb Res. 2019 Mar;175:32-36. doi: 10.1016/j.thromres.2019.01.010. Epub 2019 Jan 18.

PMID:
30685523
14.

The benefit of betrixaban for the extended thromboprophylaxis in acutely ill medical patients.

Scarpa D, Denas G, Babuin L, Pengo V.

Expert Opin Pharmacother. 2019 Feb;20(3):261-268. doi: 10.1080/14656566.2018.1558209. Epub 2019 Jan 7. Review.

PMID:
30615495
15.

Prevalence of antiphospholipid (aPL) antibodies among patients with chronic thromboembolic pulmonary hypertension: a systematic review and meta-analysis.

Cheng CY, Zhang YX, Denas G, Du Y, Jing ZC, Pengo V.

Intern Emerg Med. 2019 Jun;14(4):521-527. doi: 10.1007/s11739-018-02021-z. Epub 2019 Jan 2.

PMID:
30603858
16.

Effect of CYP4F2, VKORC1, and CYP2C9 in Influencing Coumarin Dose: A Single-Patient Data Meta-Analysis in More Than 15,000 Individuals.

Danese E, Raimondi S, Montagnana M, Tagetti A, Langaee T, Borgiani P, Ciccacci C, Carcas AJ, Borobia AM, Tong HY, Dávila-Fajardo C, Rodrigues Botton M, Bourgeois S, Deloukas P, Caldwell MD, Burmester JK, Berg RL, Cavallari LH, Drozda K, Huang M, Zhao LZ, Cen HJ, Gonzalez-Conejero R, Roldan V, Nakamura Y, Mushiroda T, Gong IY, Kim RB, Hirai K, Itoh K, Isaza C, Beltrán L, Jiménez-Varo E, Cañadas-Garre M, Giontella A, Kringen MK, Haug KBF, Gwak HS, Lee KE, Minuz P, Lee MTM, Lubitz SA, Scott S, Mazzaccara C, Sacchetti L, Genç E, Özer M, Pathare A, Krishnamoorthy R, Paldi A, Siguret V, Loriot MA, Kutala VK, Suarez-Kurtz G, Perini J, Denny JC, Ramirez AH, Mittal B, Rathore SS, Sagreiya H, Altman R, Shahin MHA, Khalifa SI, Limdi NA, Rivers C, Shendre A, Dillon C, Suriapranata IM, Zhou HH, Tan SL, Tatarunas V, Lesauskaite V, Zhang Y, Maitland-van der Zee AH, Verhoef TI, de Boer A, Taljaard M, Zambon CF, Pengo V, Zhang JE, Pirmohamed M, Johnson JA, Fava C.

Clin Pharmacol Ther. 2019 Jun;105(6):1477-1491. doi: 10.1002/cpt.1323. Epub 2019 Feb 17.

PMID:
30506689
17.

Optimizing quality care for the oral vitamin K antagonists (VKAs).

Pengo V, Denas G.

Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):332-338. doi: 10.1182/asheducation-2018.1.332. Review.

PMID:
30504329
18.

Lupus anticoagulant identifies two distinct groups of patients with different antibody patterns.

Pengo V, Del Ross T, Ruffatti A, Bison E, Cattini MG, Pontara E, Testa S, Legnani C, Pozzi N, Peterle D, Acquasaliente L, De Filippis V, Denas G.

Thromb Res. 2018 Dec;172:172-178. doi: 10.1016/j.thromres.2018.11.003. Epub 2018 Nov 9.

PMID:
30466070
19.

Prevention of atherothrombotic events in patients with diabetes mellitus: from antithrombotic therapies to new-generation glucose-lowering drugs.

Patti G, Cavallari I, Andreotti F, Calabrò P, Cirillo P, Denas G, Galli M, Golia E, Maddaloni E, Marcucci R, Parato VM, Pengo V, Prisco D, Ricottini E, Renda G, Santilli F, Simeone P, De Caterina R; Working Group on Thrombosis of the Italian Society of Cardiology.

Nat Rev Cardiol. 2019 Feb;16(2):113-130. doi: 10.1038/s41569-018-0080-2. Review.

PMID:
30250166
20.

Risk of reoperation in bioprosthetic valve patients with indication for long-term anticoagulation. Results from the observational retrospective multicentre PLECTRUM study.

Poli D, Antonucci E, Pengo V, Grifoni E, Maggini N, Testa S, Lodigiani C, Insana A, Marongiu F, Barcellona D, Paparo C, Bucherini E, Pignatelli P, Palareti G.

Open Heart. 2018 Aug 27;5(2):e000837. doi: 10.1136/openhrt-2018-000837. eCollection 2018.

21.

Factors associated with first thrombosis in patients presenting with obstetric antiphospholipid syndrome (APS) in the APS Alliance for Clinical Trials and International Networking Clinical Database and Repository: a retrospective study.

de Jesús GR, Sciascia S, Andrade D, Barbhaiya M, Tektonidou M, Banzato A, Pengo V, Ji L, Meroni PL, Ugarte A, Cohen H, Branch DW, Andreoli L, Belmont HM, Fortin PR, Petri M, Rodriguez E, Cervera R, Knight JS, Atsumi T, Willis R, Nascimento IS, Rosa R, Erkan D, Levy RA; APS ACTION.

BJOG. 2019 Apr;126(5):656-661. doi: 10.1111/1471-0528.15469. Epub 2018 Oct 24.

PMID:
30222236
22.

Catastrophic antiphospholipid syndrome: Lessons from 14 cases successfully treated in a single center. A narrative report.

Ruffatti A, De Silvestro G, Marson P, Tonello M, Calligaro A, Favaro M, Del Ross T, Hoxha A, Mattia E, Pengo V.

J Autoimmun. 2018 Sep;93:124-130. doi: 10.1016/j.jaut.2018.07.001. Epub 2018 Jul 7.

PMID:
30146007
23.

The American College of Chest Physician score to assess the risk of bleeding during anticoagulation in patients with venous thromboembolism.

Palareti G, Antonucci E, Mastroiacovo D, Ageno W, Pengo V, Poli D, Testa S, Tosetto A, Prandoni P.

J Thromb Haemost. 2018 Oct;16(10):1994-2002. doi: 10.1111/jth.14253. Epub 2018 Aug 24.

PMID:
30059189
24.

Impact of Chronic Renal Failure on Ischemic and Bleeding Events at 1 Year in Patients With Acute Coronary Syndrome (from the Multicenter START ANTIPLATELET Registry).

Patti G, Ricottini E, Nenna A, Cavallari I, Antonucci E, Calabrò P, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Bisignani A, Marcucci R.

Am J Cardiol. 2018 Sep 15;122(6):936-943. doi: 10.1016/j.amjcard.2018.05.049. Epub 2018 Jun 27.

PMID:
30057232
25.

Diagnostics and treatment of thrombotic antiphospholipid syndrome (APS): A personal perspective.

Pengo V, Denas G.

Thromb Res. 2018 Sep;169:35-40. doi: 10.1016/j.thromres.2018.07.011. Epub 2018 Jul 7. Review.

PMID:
30007134
26.

Laboratory criteria for antiphospholipid syndrome: reply.

Devreese KMJ, Ortel TL, Pengo V, de Laat B.

J Thromb Haemost. 2018 Oct;16(10):2117-2119. doi: 10.1111/jth.14238. Epub 2018 Aug 16. No abstract available.

PMID:
30007111
27.

Risk factors for intracranial hemorrhage during vitamin K antagonist therapy in patients with nonvalvular atrial fibrillation: A case-control study.

Zanella L, Zoppellaro G, Marigo L, Denas G, Padayattil Jose S, Pengo V.

Cardiovasc Ther. 2018 Oct;36(5):e12458. doi: 10.1111/1755-5922.12458. Epub 2018 Jul 30.

PMID:
30007110
28.

Rivaroxaban vs warfarin in high-risk patients with antiphospholipid syndrome.

Pengo V, Denas G, Zoppellaro G, Jose SP, Hoxha A, Ruffatti A, Andreoli L, Tincani A, Cenci C, Prisco D, Fierro T, Gresele P, Cafolla A, De Micheli V, Ghirarduzzi A, Tosetto A, Falanga A, Martinelli I, Testa S, Barcellona D, Gerosa M, Banzato A.

Blood. 2018 Sep 27;132(13):1365-1371. doi: 10.1182/blood-2018-04-848333. Epub 2018 Jul 12.

PMID:
30002145
29.

McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome.

Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A.

J Thromb Haemost. 2018 Jun 7. doi: 10.1111/jth.14192. [Epub ahead of print]

PMID:
29978552
30.

Gender-Related Differences in Antiplatelet Therapy and Impact on 1-Year Clinical Outcome in Patients Presenting With ACS: The START ANTIPLATELET Registry.

Cirillo P, Di Serafino L, Patti G, Antonucci E, Calabrò P, Gresele P, Palareti G, Pengo V, Pignatelli P, Marcucci R.

Angiology. 2019 Mar;70(3):257-263. doi: 10.1177/0003319718783866. Epub 2018 Jul 3.

PMID:
29969919
31.

Mechanical prosthetic heart valves: Quality of anticoagulation and thromboembolic risk. The observational multicenter PLECTRUM study.

Poli D, Antonucci E, Pengo V, Migliaccio L, Testa S, Lodigiani C, Coffetti N, Facchinetti R, Serricchio G, Falco P, Mangione C, Masottini S, Ruocco L, De Caterina R, Palareti G; Italian Federation of Anticoagulation Clinics.

Int J Cardiol. 2018 Sep 15;267:68-73. doi: 10.1016/j.ijcard.2018.04.042.

PMID:
29957264
32.

Clinical value of anti-domain I-β2Glycoprotein 1 antibodies in antiphospholipid antibody carriers. A single centre, prospective observational follow-up study.

Tonello M, Mattia E, Del Ross T, Favaro M, Calligaro A, Hoxha A, Bison E, Pengo V, Ruffatti A.

Clin Chim Acta. 2018 Oct;485:74-78. doi: 10.1016/j.cca.2018.06.037. Epub 2018 Jun 25.

PMID:
29953850
33.

Management of major bleeding and outcomes in patients treated with direct oral anticoagulants: results from the START-Event registry.

Testa S, Ageno W, Antonucci E, Morandini R, Beyer-Westendorf J, Paciaroni M, Righini M, Sivera P, Verhamme P, Pengo V, Poli D, Palareti G.

Intern Emerg Med. 2018 Oct;13(7):1051-1058. doi: 10.1007/s11739-018-1877-z. Epub 2018 May 22.

PMID:
29790125
34.

Different safety profiles of oral anticoagulants in very elderly non-valvular atrial fibrillation patients. A retrospective propensity score matched cohort study.

Zoppellaro G, Zanella L, Denas G, Gennaro N, Ferroni E, Fedeli U, Padayattil Jose S, Costa G, Corti MC, Andretta M, Pengo V.

Int J Cardiol. 2018 Aug 15;265:103-107. doi: 10.1016/j.ijcard.2018.04.117. Epub 2018 Apr 25. No abstract available.

PMID:
29728333
35.

Commentary.

Pengo V.

Clin Chem. 2018 May;64(5):781. doi: 10.1373/clinchem.2017.282053. No abstract available.

36.

The vexed question of whether or not to measure levels of direct oral anticoagulants before surgery or invasive procedures.

Tripodi A, Marongiu F, Moia M, Palareti G, Pengo V, Poli D, Prisco D, Testa S, Zanazzi M.

Intern Emerg Med. 2018 Oct;13(7):1029-1036. doi: 10.1007/s11739-018-1854-6. Epub 2018 Apr 26. Review.

PMID:
29700696
37.

The Impact of Systemic Lupus Erythematosus on the Clinical Phenotype of Antiphospholipid Antibody-Positive Patients: Results From the AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Clinical Database and Repository.

Unlu O, Erkan D, Barbhaiya M, Andrade D, Nascimento I, Rosa R, Banzato A, Pengo V, Ugarte A, Gerosa M, Ji L, Efthymiou M, Branch DW, de Jesus GR, Tincani A, Belmont HM, Fortin PR, Petri M, Rodriguez E, Pons-Estel GJ, Knight JS, Atsumi T, Willis R, Zuily S, Tektonidou MG; AntiPhospholipid Syndrome Alliance for Clinical Trials and InternatiOnal Networking Investigators.

Arthritis Care Res (Hoboken). 2019 Jan;71(1):134-141. doi: 10.1002/acr.23584.

PMID:
29669399
38.

Epidemiology and Management of Patients With Acute Coronary Syndromes in Contemporary Real-World Practice: Evolving Trends From the EYESHOT Study to the START-ANTIPLATELET Registry.

Calabrò P, Gragnano F, Di Maio M, Patti G, Antonucci E, Cirillo P, Gresele P, Palareti G, Pengo V, Pignatelli P, Pennacchi M, Granatelli A, De Servi S, De Luca L, Marcucci R; for EYESHOT Study and Start Antiplatelet Register.

Angiology. 2018 Oct;69(9):795-802. doi: 10.1177/0003319718760917. Epub 2018 Mar 15.

PMID:
29544348
39.

Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH.

Devreese KMJ, Ortel TL, Pengo V, de Laat B; Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies.

J Thromb Haemost. 2018 Apr;16(4):809-813. doi: 10.1111/jth.13976. Epub 2018 Mar 13. No abstract available.

PMID:
29532986
40.

Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants.

Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B, Pengo V, Poli D, Morandini R, Testa R, Tripodi A, Palareti G.

J Thromb Haemost. 2018 May;16(5):842-848. doi: 10.1111/jth.14001. Epub 2018 Apr 17.

PMID:
29532628
41.

Effect of Additional Treatments Combined with Conventional Therapies in Pregnant Patients with High-Risk Antiphospholipid Syndrome: A Multicentre Study.

Ruffatti A, Tonello M, Hoxha A, Sciascia S, Cuadrado MJ, Latino JO, Udry S, Reshetnyak T, Costedoat-Chalumeau N, Morel N, Marozio L, Tincani A, Andreoli L, Haladyj E, Meroni PL, Gerosa M, Alijotas-Reig J, Tenti S, Mayer-Pickel K, Simchen MJ, Bertero MT, De Carolis S, Ramoni V, Mekinian A, Grandone E, Maina A, Serrano F, Pengo V, Khamashta MA.

Thromb Haemost. 2018 Apr;118(4):639-646. doi: 10.1055/s-0038-1632388. Epub 2018 Feb 28.

42.

Special issue: Late consequences of venous thromboembolism.

Kahn SR, Pengo V.

Thromb Res. 2018 Apr;164:99. doi: 10.1016/j.thromres.2018.02.005. Epub 2018 Feb 13. No abstract available.

PMID:
29459016
43.

Field evaluation of the safety, acceptability, and feasibility of early infant male circumcision using the AccuCirc device.

Bailey RC, Nyaboke I, Mackesy-Amiti ME, Okello E, Pengo V, Ochomo B, Auma ME, Were S, Ojuok S, Adoyo E, Adhiambo M, Young MR, Plank RM, Otieno FO.

PLoS One. 2018 Feb 14;13(2):e0191501. doi: 10.1371/journal.pone.0191501. eCollection 2018.

44.

Point of Care Testing (POCT) to assess drug concentration in patients treated with non-vitamin K antagonist oral anticoagulants (NOACs).

Padayattil Jose S, Banzato A, Carraro P, Haleh A, Rossi K, Nante G, Denas G, Zoppellaro G, Pengo V.

Thromb Res. 2018 Mar;163:100-104. doi: 10.1016/j.thromres.2018.01.044. Epub 2018 Feb 6.

PMID:
29407620
45.

Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.

Zambon CF, Pengo V, Moz S, Bozzato D, Fogar P, Padoan A, Plebani M, Groppa F, De Rosa G, Padrini R.

Eur J Clin Pharmacol. 2018 May;74(5):571-582. doi: 10.1007/s00228-018-2422-8. Epub 2018 Feb 2.

PMID:
29396738
46.

Thrombocytopenia in high-risk patients with antiphospholipid syndrome.

Pontara E, Banzato A, Bison E, Cattini MG, Baroni G, Denas G, Calligaro A, Marson P, Tison T, Ruffatti A, Pengo V.

J Thromb Haemost. 2018 Mar;16(3):529-532. doi: 10.1111/jth.13947. Epub 2018 Jan 25.

PMID:
29316193
47.

Comparison of five specific assays for determination of dabigatran plasma concentrations in patients enrolled in the START-Laboratory Register.

Cini M, Legnani C, Cosmi B, Testa S, Dellanoce C, Paoletti O, Marcucci R, Poli D, Paniccia R, Pengo V, Tripodi A, Palareti G; START-Laboratory Register.

Int J Lab Hematol. 2018 Apr;40(2):229-236. doi: 10.1111/ijlh.12772. Epub 2018 Jan 3.

PMID:
29314632
48.

Warfarin prescription in patients with nonvalvular atrial fibrillation and one non-gender-related risk factor (CHA2 DS2 VASc 1 or 2): A treatment dilemma.

Denas G, Zoppellaro G, Padayattil Jose S, Antonucci E, Marongiu F, Poli D, Testa S, Tripodi A, Palareti G, Pengo V.

Cardiovasc Ther. 2018 Feb;36(1). doi: 10.1111/1755-5922.12310. Epub 2017 Nov 11.

PMID:
29078033
49.

Data from a multidisciplinary poll of 178 expert physicians on the usage of non-vitamin K Oral Anticoagulants in patients with atrial fibrillation and venous thromboembolism.

Colonna P, Andreotti F, Ageno W, Pengo V, Marchionni N.

Data Brief. 2017 Oct 6;15:532-539. doi: 10.1016/j.dib.2017.09.064. eCollection 2017 Dec.

50.

International collaborative study for the calibration of proposed International Standards for thromboplastin, rabbit, plain, and for thromboplastin, recombinant, human, plain.

van den Besselaar AMHP, Chantarangkul V, Angeloni F, Binder NB, Byrne M, Dauer R, Gudmundsdottir BR, Jespersen J, Kitchen S, Legnani C, Lindahl TL, Manning RA, Martinuzzo M, Panes O, Pengo V, Riddell A, Subramanian S, Szederjesi A, Tantanate C, Herbel P, Tripodi A.

J Thromb Haemost. 2018 Jan;16(1):142-149. doi: 10.1111/jth.13879. Epub 2017 Dec 1.

PMID:
29065247

Supplemental Content

Support Center